Related Experiment Video

Updated: Mar 24, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

3.0K

Potential Molecular Targets for Narrow-Spectrum Agents to Combat Mycoplasma pneumoniae Infection and Disease

Mitchell F Balish1, Steven L Distelhorst1

  • 1Department of Microbiology, Miami University Oxford, OH, USA.

Frontiers in Microbiology
|March 5, 2016
PubMed

Insights

Growing macrolide resistance in Mycoplasma pneumoniae necessitates novel narrow-spectrum drugs. Understanding M. pneumoniae biology is key to developing effective, long-term therapies targeting specific pathways or molecules.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Mycoplasma pneumoniae exhibits increasing global resistance to macrolide antibiotics.
  • Cross-resistance in other Mycoplasma species suggests fluoroquinolones may offer limited long-term utility.
  • Broad-spectrum antibiotics can disrupt patient microbiota, leading to adverse health effects.

Purpose of the Study:

  • To review potential targets for new, narrow-spectrum antibiotics against M. pneumoniae.
  • To evaluate the advantages and disadvantages of targeting specific M. pneumoniae molecules, pathways, or functions.
  • To guide research priorities for developing effective M. pneumoniae therapies.

Main Methods:

  • Literature review of M. pneumoniae biology and antibiotic resistance mechanisms.
  • Analysis of potential drug targets including toxic molecules, metabolic pathways, and attachment/motility factors.
  • Evaluation of the impact of narrow-spectrum agents on M. pneumoniae and host microbiota.

Main Results:

  • Identified key areas of M. pneumoniae biology requiring further investigation for drug development.
  • Discussed the potential benefits of narrow-spectrum agents in preserving host microbiota.
  • Highlighted the risks associated with broad-spectrum antibiotic use.

Conclusions:

  • Developing narrow-spectrum drugs targeting M. pneumoniae is crucial due to rising resistance.
  • A comprehensive understanding of M. pneumoniae's basic biology is essential for identifying effective drug targets.
  • Targeting specific M. pneumoniae vulnerabilities offers a promising strategy for sustainable treatment.
Keywords:
adherenceantibioticsmetabolismmycoplasmatoxins

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.3K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
17
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
60
Bacterial Phylum Tenericutes01:24

Bacterial Phylum Tenericutes

The phylum Tenericutes, which includes the single class Mollicutes, comprises bacteria that lack cell walls. The term "Mollicutes" derives from the Latin word mollis, meaning "soft." These organisms are among the smallest known and are commonly referred to as mycoplasmas due to the prominence of the genus Mycoplasma, which includes well-known human pathogens. Despite their inability to stain gram-positively (a result of their lack of cell walls), mycoplasmas are phylogenetically related to the...
581
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
22
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
25
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
24